about ibd

New treatment modalities needed to reduce symptoms and long term complications

Ulcerative colitis and Crohn’s disease, the two main forms of inflammatory bowel disease (IBD), are both chronic relapsing diseases characterized by the inflammation of parts of the gastrointestinal tract.

Only in North America, more than 3 millions of people are suffering from this debilitating condition. Currently available medications alleviate inflammation but still do not prevent long term complications.

The Challenge Remains

Cure and Care

What is IBD

Inflammatory bowel disease (IBD) is the name of a group of disorders that cause the intestines to become inflamed and ulcerated. The main forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC).

Symptoms

Patient with IBD experience symptoms such as abdominal pain, rectal bleeding, fatigue, vomiting, diarrhea, weight loss and anemia.

Disease management

IBD is a life-long disease with a typical onset in adolescence and early adult. Although people with IBD lead normal lives most of the time, the unpredictability of the symptoms and the medications need negatively impact the quality of life.

There is no cure to IBD. Therapies focus on symptoms management and maintaining remission using anti-inflammatory agents.

IBD pathogenesis

It is widely accepted that IBD is the result of dysregulated gut mucosal immune responses to environmental factors in genetically-predisposed individuals.

Ulcerative Colitis

Inflammation is more localized in ulcerative colitis and typically affect the large intestine (colon) and the rectum (proctosigmoiditis exemplified in red)

Ulcerative colitis and Crohn's disease

What is the difference?

Ulcerative colitis (A) is confine to the large intestine with a continuous distribution starting from the anus and affecting only the mucosa of the colon. Even though Crohn’s disease most commonly affects the terminal ileum and the colon, it may involve any part of the GIT (B). CD is discontinuous and the inflammation may extend through the entire thickness of the wall of the intestine.

Crohn's disease

Inflammation from Crohn’s can strike anywhere in the gastrointestinal tract with inflamed patches interspersed between healthy portions of the gut (exemplified in red)

the unmet medical need

Targeting moderate-to-severe UC and 5-ASA non-responders as a steroid sparing therapy and a safer alternative to biologics

Ulcerative colitis and Crohn’s disease, the two main forms of inflammatory bowel disease (IBD), are both chronic relapsing diseases characterized by the inflammation of parts of the gastrointestinal tract.

Only in North America, more than 3 millions of poeple are suffering from this debilitating condition. Currently available medications alleviate inflammation but still do not prevent long term complications.

2021 Giiant Pharma All Rights Reserved